Seroprevalencia de hepatitis viral B en estudiantes universitarios en Abancay, Perú

Costo-efectividad de dos terapias antivirales para hepatitis B crónica en el Perú: entecavir y tenofovir

“…Chacaltana et al reportan en personal militar una seroprevalencia de HbsAg de 0,33, y 0,58% para anticuerpos anti-Hbc (11) . Dos estudios en Abancay, que incluyeron estudiantes universitarios y donantes de sangre en un hospital público, reportan frecuencias de HbsAg del 2,5 y 1,9%, respectivamente, y de anticuerpos anti-HbcAg del 28,3 y 35% (12,13) . Finalmente, se ha reportado que la población indígena de la Amazonía sería una de las más afectadas, con una seroprevalencia de HbsAg de 2,1% en gestantes y 4% en sus parejas, así como una seroprevalencia de anticuerpos anti-HbcAg de 42,1% en gestantes y 54,1% en sus parejas (14) .…”

Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B

“…The program began with immunization of 3791 children aged under 5 years between 1991 and 1994, and subsequently expanded to universal vaccination in Abancay as well as other hyperendemic provinces in Peru [ 10 ]. Following implementation of the program against HBV, the carrier rate of HBsAg decreased from 9.8% in 1991 (in the general Abancay population) [ 11 ] to below 3% in 2010 among those aged ≥18 years (including 2.5% and 1.9% of university students and blood donors, respectively) [ 12 , 13 ]. Over the next 22 years, this vaccination program has also led to a decline in the mortality burden of HBV-related liver diseases, particularly cirrhosis and fulminant hepatitis, in children aged under 15 years [ 14 ].…”

“…Despite the benefits of the vaccination program in terms of lower carrier rates of HBsAg in those aged ≥18 years and reduced mortality rates from HBV-related liver diseases [ 12 – 14 ], to date, there are no data on the impact of the HBV vaccination program on the carrier rates of HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs) and hepatitis D antibody (anti-HDV) in the general population of Abancay. Therefore, in this study, we determined the prevalence of HBV and HDV infections in Abancay province 23 years since the introduction of the first pilot vaccination program against HBV, as well as the post-vaccine response against hepatitis B in terms of prevalence of anti-HBs.…”